FDA Panel Backs Pfizer Inc.'s Drug for Kidney Cancer
SILVER SPRING, Md., Dec 7 - Pfizer Inc won unanimous expert backing for its Inlyta experimental drug for patients with advanced kidney cancer.
A Food and Drug Administration advisory committee voted 13-0 on Wednesday that the drug, also called axitinib, had a favorable benefit-risk profile for such patients after initial treatment has failed.
A Food and Drug Administration advisory committee voted 13-0 on Wednesday that the drug, also called axitinib, had a favorable benefit-risk profile for such patients after initial treatment has failed.